Opendata, web and dolomites


The first effective remedy for acute pancreatitis disease

Total Cost €


EC-Contrib. €






 RAPID project word cloud

Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.

plan    undergo    orientale    burden    admitted    data    yearly    emergency    operated    39    visits    phases    trigger    position    orphan    tech    globally    duchenne    off    dossier    company    acute    ap    patented    pave    gastroenterology    cellular    solution    frequent    patients    providers    ready    prior    muscular    ions    generating    million    endoscopic    spin    costing    hyper    discharge    care    intensive    chemicare    healthcare    prepare    molecules    drug    frame    rapid    clinical    ema    rare    preclinically    surgical    fda    finance    aggregate    services    candidate    initiation    designation    proved    preclinical    national    optimal    trials    paths    university    revenues    reinvested    piemonte    pharmacological    innovation    store    indications    validate    advantage    license    2024    modulate    therapies    breakthrough    capacity    cluster    overload    small    last    pharma    activation    myopathy    diseases    calcium    accelerated    validation    market    disease    tubular    pancreatitis    time    regulatory    entry    people    hospitalizations    diagnosis    solutions    therapeutic    complete    dystrophy    health    room    utmost   

Project "RAPID" data sheet

The following table provides information about the project.


Organization address
address: VIA AMICO CANOBIO 4/6
city: NOVARA
postcode: 28100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHEMICARE SARL IT (NOVARA) coordinator 50˙000.00


 Project objective

ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

ChromicGlass (2019)


Read More